Research and development expenses consist of the following at December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013:
| December 31, 2013 | December 31, 2012 | For the period from March 11, 2011 through December 31, 2013 | |||||||
| External service provider costs: | |||||||||
| Sparsentan | $ | 2,443,273 | $ | 297,833 | $ | 2,619,723 | |||
| RE-024 | 1,548,957 | 124,635 | 1,673,592 | ||||||
| Weg license in process R&D (Note 13) | 1,000,000 | - | 1,000,000 | ||||||
| Syntocinon | 250,540 | - | 250,540 | ||||||
| RE-034 | 230,279 | - | 230,279 | ||||||
| General | 159,080 | 240,034 | 493,569 | ||||||
| Other product candidates | 117,771 | - | 376,710 | ||||||
| Total external service provider costs: | 5,749,900 | 662,502 | 6,644,413 | ||||||
| Internal personnel costs (inclusive of share base compensation $259,076, $0, and $259,076): | 1,334,109 | - | 1,334,109 | ||||||
| Total research and development | $ | 7,084,009 | $ | 662,502 | $ | 7,978,522 |